Vincent Medical Holdings Limited (“Vincent Medical” or together with its subsidiaries, the “Group”, stock code: 1612) is pleased to announce that its O2FLO Respiratory Unit (with model number: VUN-001, the “Unit”) has received approval from the National Medical Products Administration (“NMPA”) of the PRC, along with its related accessories and disposables. Following the approval from Japan’s Ministry of Health, Labour, and Welfare and Conformité Européenne (“CE”) Mark, this represented yet another successful registration for the same device, as the Group continued to drive its OBM development while transforming into a comprehensive respiratory medical device provider for both disposables and equipment.
The Unit, a non-invasive high flow oxygen therapy device, is used in the treatment of patients with chronic or acute respiratory distress such as pneumonia, viral pneumonia, chronic obstructive pulmonary disease, heart failure, and asthma. It has been clinically proven that the utilization of high flow oxygen therapy can improve oxygenation, reduce the patient’s work of breathing and serve as a more economical and safer alternative to invasive mechanical ventilation. Apart from the PRC, Japan and the European Union, the Group is also committed to registering and launching the device in the United States and other countries.